The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,022
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy
Couturier, C., Ayyadhury, S., Le, P. U., Nadaf, J., Monlong, J., Riva, G., Allache, R., Baig, S., Yan, X., Bourgey, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17186-5 · Cited by 577
Emerging insights into the molecular and cellular basis of glioblastomaPreprint
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 573
Self-citationDedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice
Friedmann‐Morvinski, D., Bushong, E. A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M. H., & Verma, I. M. (2012) · Science · doi:10.1126/science.1226929 · Cited by 566
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro-Munoz, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 575
Self-citationDelineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
Witt, H., Mack, S. C., Ryzhova, M. V., Bender, S., Sill, M., Isserlin, R., Benner, A., Hielscher, T., Milde, T., Remke, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.007 · Cited by 554
Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 571
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Self-citationJoint and individual variation explained (JIVE) for integrated analysis of multiple data types
Lock, E. F., Hoadley, K. A., Marron, J. S., & Nobel, A. B. (2013) · The Annals of Applied Statistics · doi:10.1214/12-aoas597 · Cited by 572
Self-citationVEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 566
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N., Huse, J. T., & Holland, E. C. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.01.005 · Cited by 553
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 536
Szerlip, N. J., Pedraza, A. M., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E. C., Huse, J. T., Jhanwar, S. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114033109 · Cited by 546
Self-citationEZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535
Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A. M., & Holland, E. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 554
Self-citationMalignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 549
Comprehensive literature review and statistical considerations for microarray meta-analysis
Tseng, G. C., Ghosh, D., & Feingold, E. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1265 · Cited by 532
Identification of diverse astrocyte populations and their malignant analogs
John Lin, C.-C., Yu, K., Hatcher, A., Huang, T.-W., Lee, H. K., Carlson, J., Weston, M. C., Chen, F., Zhang, Y., Zhu, W., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4493 · Cited by 525
Glioblastoma: defining tumor niches
Hambardzumyan, D., & Bergers, G. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.009 · Cited by 522
Epidemiology and Outcome of Glioblastoma
Tamimi, A., & Juweid, M. E. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch8 · Cited by 526
Glioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 531
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517
Self-citationBrain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake
Flavahan, W. A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A. E., Weil, R. J., Nakano, I., Sarkaria, J. N., Stringer, B. W., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3510 · Cited by 511
Self-citationEmerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 546
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Glioma progression is shaped by genetic evolution and microenvironment interactions
Varn, F. S., Johnson, K. C., Martinek, J., Huse, J. T., Nasrallah, M. P., Wesseling, P., Cooper, L., Malta, T. M., Wade, T. E., Sabedot, T. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.038 · Cited by 516
Self-citationA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3911 · Cited by 503
Emerging patterns of somatic mutations in cancer
Watson, I. R., Takahashi, K., Futreal, P. A., & Chin, L. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3539 · Cited by 497
Cancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 491
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., Pleier, S. V., Bai, A. H. C., Karra, D., Piro, R. M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3217 · Cited by 486
Wirsching, H., Galanis, E., & Weller, M. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 532
NF-κB addiction and its role in cancer: ‘one size does not fit all’
Chaturvedi, M., Sung, B., Yadav, V. R., Kannappan, R., & Aggarwal, B. B. (2010) · Oncogene · doi:10.1038/onc.2010.566 · Cited by 485
Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
Abdelfattah, N., Kumar, P., Wang, C., Leu, J.-S., Flynn, W. F., Gao, R., Baskin, D. S., Pichumani, K., Ijare, O. B., Wood, S. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28372-y · Cited by 469
Suppression of lung adenocarcinoma progression by Nkx2-1
Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., et al. (2011) · Nature · doi:10.1038/nature09881 · Cited by 467
Self-citationDiffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 478
Current concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöehrer, A., Erridge, S., Hegi, M. E., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 468
Lei, Z., Tan, I. B., Das, K., Deng, N., Zouridis, H., Pattison, S. T., Chua, C., Feng, Z., Guan, Y. K., Ooi, C.-H., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.010 · Cited by 468
IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 477
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 468
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cellsPreprint
Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J. H., Clément‐Schatlo, V., Radovanovic, I., Rheinbay, E., Provero, P., & Stamenkovic, I. (2012) · Genes & Development · doi:10.1101/gad.188292.112 · Cited by 454
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., Nelson, S. F., & Liau, L. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2563 · Cited by 448
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 448
Survival and low-grade glioma: the emergence of genetic information
Claus, E. B., Walsh, K. M., Wiencke, J. K., Molinaro, A. M., Wiemels, J. L., Schildkraut, J. M., Bondy, M. L., Berger, M. S., Jenkins, R. B., & Wrensch, M. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus12367 · Cited by 455
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Gabrusiewicz, K. R., Rodriguez, B. A. T., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G. A., Zhou, S., Wang, Q., Elakkad, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85841 · Cited by 455
Cancer-associated pathways and biomarkers of venous thrombosis
Hisada, Y., & Mackman, N. (2017) · Blood · doi:10.1182/blood-2017-03-743211 · Cited by 445
Brain malignancies: Glioblastoma and brain metastases
Lah, T. T., Novak, M., & Breznik, B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.010 · Cited by 454
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaïh, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 460
Immune Microenvironment in Glioblastoma Subtypes
Chen, Z., & Hambardzumyan, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01004 · Cited by 449
Lai, A., Kharbanda, S., Pope, W. B., Tran, A. N., Solis, O. E., Peale, F. V., Jr., Forrest, W. F., Pujara, K., Carrillo, J., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 440
Self-citationLiu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A. J., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 443
Schuster, J. M., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugała, M. M., Jensen, R. L., Baehring, J. M., Sloan, A. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Gutman, D. A., Cooper, L., Hwang, S. N., Holder, C. A., Gao, J., Aurora, T. D., Dunn, W. D., Scarpace, L. M., Mikkelsen, T., Jain, R., et al. (2013) · Radiology · doi:10.1148/radiol.13120118 · Cited by 417
The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A. M., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A. M., Yu, B., Somasekharan, S. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 428
Ludwig, K., & Kornblum, H. I. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2379-y · Cited by 419
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Kohanbash, G., Carrera, D. A., Shrivastav, S., Ahn, B. J., Jahan, N., Mazor, T., Chheda, Z. S., Downey, K., Watchmaker, P. B., Beppler, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90644 · Cited by 420
Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression
Yee, P. P., Wei, Y., Kim, S. Y., Lu, T., Chih, S. Y., Lawson, C., Tang, M., Liu, Z., Anderson, B., Thamburaj, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19193-y · Cited by 417
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Self-citationBao, Z., Chen, H.-M., Yang, M.-Y., Zhang, C., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J. C., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 409
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
Qazi, M. A., Vora, P., Venugopal, C., Sidhu, S. S., Moffat, J., Swanton, C., & Singh, S. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx169 · Cited by 413
Stacpoole, P. W. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx071 · Cited by 418
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., Guilhamon, P., Lee, L., Kushida, M. M., Pellacani, D., et al. (2017) · Nature · doi:10.1038/nature23666 · Cited by 399
Castro, D. S., Martynoga, B., Parras, C. M., Ramesh, V., Pacary, E., Johnston, C., Drechsel, D., Lebel, M., Garcia, L. G., Hunt, C., et al. (2011) · Genes & Development · doi:10.1101/gad.627811 · Cited by 414
Mechanisms of PTEN loss in cancer: It’s all about diversity
Garcia, V. A., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 407
Chen, X., Wanggou, S., Bodalia, A., Zhu, M. S., Dong, W., Fan, J. J., Yin, W. C., Min, H.-K., Hu, M., Draghici, D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.046 · Cited by 401
Personalized Medicine: Progress and Promise
Chan, I. S., & Ginsburg, G. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101446 · Cited by 409
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 404
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Self-citationYang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S. M., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 395
Federated learning enables big data for rare cancer boundary detection
Pati, S., Baid, U., Edwards, B., Sheller, M., Wang, S.-H., Reina, G. A., Foley, P., Gruzdev, A., Karkada, D., Davatzikos, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33407-5 · Cited by 394
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 417
Glioblastoma Model Using Human Cerebral Organoids
Ogawa, J., Pao, G. M., Shokhirev, M. N., & Verma, I. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.105 · Cited by 391
Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma
Ozawa, T., Riester, M., Cheng, Y.-K., Huse, J. T., Squatrito, M., Helmy, K. Y., Charles, N. A., Michor, F., & Holland, E. C. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.005 · Cited by 393
Critical limitations of consensus clustering in class discovery
Şenbabaoğlu, Y., Michailidis, G. C., & Li, J. Z. (2014) · Scientific Reports · doi:10.1038/srep06207 · Cited by 385
Tumor Purity as an Underlying Key Factor in Glioma
Zhang, C., Cheng, W., Ren, X., Wang, Z., Liu, X., Li, G., Han, S., Jiang, T., & Wu, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2598 · Cited by 377
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M. M., Bayani, J., Pressey, J. C., Lionel, A. C., Clarke, I. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320611111 · Cited by 394
Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Jin, X., Kim, L. J. Y., Wu, Q., Wallace, L. C., Prager, B. C., Sanvoranart, T., Gimple, R. C., Wang, X., Mack, S. C., Miller, T. E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4415 · Cited by 388
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0002-y · Cited by 385
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrübl, F. A., Silver, D. J., Tügertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 399
Wen, P. Y., Stein, A., van den Bent, M. J., Greve, J. D., Wick, A., Vos, F. D., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 377
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant gliomaPreprint
Bhat, K., Salazar, K. L., Balasubramaniyan, V., Wani, K., Heathcock, L. E., Hollingsworth, F., James, J. D., Gumin, J., Alfaro-Munoz, K. D., Kim, S. H., et al. (2011) · Genes & Development · doi:10.1101/gad.176800.111 · Cited by 385
Keck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M. M., Rieke, D. T., Endhardt, K., Fang, P., Brägelmann, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 378
The first five years of single-cell cancer genomics and beyondPreprint
Navin, N. E. (2015) · Genome Research · doi:10.1101/gr.191098.115 · Cited by 377
Garofano, L., Migliozzi, S., Oh, Y. T., D’Angelo, F., Najac, R. D., Ko, A., Frangaj, B., Caruso, F. P., Yu, K., Yuan, J., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00159-4 · Cited by 380
Kuo, C. S., Pavlidis, S. P., Loza, M. J., Baribaud, F., Rowe, A., Pandis, I., Sousa, A. R., Corfield, J., Djukanović, R., Lutter, R., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02135-2016 · Cited by 370
Multiplexed Profiling of Single Extracellular Vesicles
Lee, K., Fraser, K. B., Ghaddar, B., Yang, K. S., Kim, E., Balaj, L., Chiocca, E. A., Breakefield, X. O., Lee, H., & Weissleder, R. (2017) · ACS Nano · doi:10.1021/acsnano.7b07060 · Cited by 369
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
Morris, L. G. T., Kaufman, A., Gong, Y., Ramaswami, D., Walsh, L. A., Turcan, Ş., Eng, S., Kannan, K. S., Zou, Y., Peng, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2538 · Cited by 375
The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation
Wang, L., Babikir, H. A., Müller, S., Yagnik, G., Shamardani, K., Catalan, F. L., Kohanbash, G., Alvarado, B., Lullo, E. D., Kriegstein, A. R., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0329 · Cited by 366
Gangoso, E., Southgate, B., Bradley, L., Lehr, S., Gálvez‐Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 365
Wang, L., Jung, J., Babikir, H. A., Shamardani, K., Jain, S., Feng, X., Gupta, N. M., Rosi, S., Chang, S., Raleigh, D. R., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00475-x · Cited by 367
Next-generation sequencing for cancer diagnostics: a practical perspective.
Meldrum, C. J., Doyle, M., & Tothill, R. W. (2011) · Europe PMC (PubMed Central) · Cited by 356
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark, V. E., Harmancı, A. S., Bai, H., Youngblood, M. W., Lee, T. I., Baranoski, J. F., Ercan‐Sencicek, A. G., Abraham, B. J., Weintraub, A. S., Hnisz, D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3651 · Cited by 356
Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
Di, J., Li, S., Li, D., Xue, H., Yang, D., & Liu, Y. (2018) · Aging · doi:10.18632/aging.101415 · Cited by 350
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 357
Wiestler, B., Capper, D., Holland-Letz, T., Korshunov, A., von Deimling, A., Pfister, S. M., Platten, M., Weller, M., & Wick, W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1156-z · Cited by 346
Metabolic Reprogramming in Glioma
Strickland, M., & Stoll, E. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00043 · Cited by 357
Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data
Yang, W., Warrington, N. M., Taylor, S. J., Whitmire, P., Carrasco, E., Singleton, K., Wu, N., Lathia, J. D., Berens, M. E., Kim, A. H., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5253 · Cited by 354
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 354
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
